Astellas Pharma Gmbh

Kotobuki Pharmaceutical Co Ltd

Kotobuki Pharmaceuticals Co., Ltd.

Kazuhiro Ikegai

Takeshi Murakami

Yoshinori Kobayashi

Atsushi Noda

Hiroshi Tomiyama

Masakazu Imamura

Eiji Kurosaki

Kayoko Kitta

Takashi Sugane

Ryota Shiraki

Fumiyoshi Iwasaki

Satoshi Miyamoto

Ryushi Seo

Tsukasa Ishihara

Toshihiro Watanabe

Hironori Harada

Hiroyuki Hisamichi

Ryuichi Takezawa

Norio Asai

Noriko Ishikawa

Ikumi Kuriwaki

Shohei Shirakami

Seijiro Akamatsu

Tetsuo Kiso

Takahiro Kuramochi

Nobuaki Takeshita

Ryotaro Ibuka

Takayuki Suzuki

Shunichiro Hachiya

Susumu Watanuki

Taisuke Takahashi

Eisuke Nozawa

Yoh Terada

Keisuke Matsuura

Makoto Oku

Tatsuya Zenkoh

Masanao Sanagi

Michihito Kageyama

Ryota Astellas Pharma Inc Shiraki

A method for preventing or treating a disease selected from the group consisting of visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia in a subject in need thereof, comprising administering to said subject an effective amount of the compound of the following formula (I) or a salt thereof: wherein R, R, R, R, R, X and n are as described herein.

Benzothiophene compound

The present invention is directed to compounds of Formula I: 

[Problems] A compound, which is useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for treating chronic renal failure and/or diabetic nephropathy, is provided. [Solving Means] The present inventors have conducted extensive studies on a compound having an EP4 receptor antagonistic activity, and confirmed that the amide compound of the present invention has an EP4 receptor antagonistic activity, thereby completing the present invention. The amide compound of the present invention has an EP4 receptor antagonistic activity, and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating various EP4-related diseases, for example, chronic renal failure and/or diabetic nephropathy, and the like.

Amide compound

To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

Piperidine derivative or salt thereof

The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via &#x2014;X&#x2014; and A ring is directly bonded to the glucose residue, and it is usable as a Na-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.

C-glycoside derivatives and salts thereof

There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).

Benzamide derivative or salt thereof

The present invention provides an azulene derivative and a salt thereof, wherein an azulene ring is bonded to a benzene ring directly or via a lower alkylene which may be substituted with a halogen atom and the benzene ring is directly bonded to the glucose residue, and it is usable as a Na-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes-related diseases such as insulin-resistant diseases and obesity.

Azulene derivatives and salts thereof

Growing community of inventors

Tokyo, Japan

Kazuhiro Ikegai